These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 11890109

  • 1. Mechanism of action of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Wang ZY.
    Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():214-8. PubMed ID: 11890109
    [Abstract] [Full Text] [Related]

  • 2. Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis.
    Chen Z, Wang ZY, Chen SJ.
    Pharmacol Ther; 1997 Feb; 76(1-3):141-9. PubMed ID: 9535176
    [Abstract] [Full Text] [Related]

  • 3. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
    Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z.
    Blood; 1997 May 01; 89(9):3345-53. PubMed ID: 9129041
    [Abstract] [Full Text] [Related]

  • 4. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
    Chen SJ, Chen LJ, Zhou GB.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb 01; 13(1):1-8. PubMed ID: 15748426
    [Abstract] [Full Text] [Related]

  • 5. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
    Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ.
    Leukemia; 2000 Feb 01; 14(2):262-70. PubMed ID: 10673743
    [Abstract] [Full Text] [Related]

  • 6. Treatment of acute promyelocytic leukemia with ATRA and As2O3: a model of molecular target-based cancer therapy.
    Fang J, Chen SJ, Tong JH, Wang ZG, Chen GQ, Chen Z.
    Cancer Biol Ther; 2002 Feb 01; 1(6):614-20. PubMed ID: 12642682
    [Abstract] [Full Text] [Related]

  • 7. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
    Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH.
    J Natl Cancer Inst; 1998 Jan 21; 90(2):124-33. PubMed ID: 9450572
    [Abstract] [Full Text] [Related]

  • 8. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z.
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun 29; 362(1482):959-71. PubMed ID: 17317642
    [Abstract] [Full Text] [Related]

  • 9. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T, Westervelt P, Hess JL.
    Mod Pathol; 2000 Sep 29; 13(9):954-61. PubMed ID: 11007035
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
    Tomita A, Kiyoi H, Naoe T.
    Int J Hematol; 2013 Jun 29; 97(6):717-25. PubMed ID: 23670176
    [Abstract] [Full Text] [Related]

  • 11. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
    Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY.
    Semin Hematol; 2001 Jan 29; 38(1):26-36. PubMed ID: 11172537
    [Abstract] [Full Text] [Related]

  • 12. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
    Zhang P.
    J Biol Regul Homeost Agents; 1999 Jan 29; 13(4):195-200. PubMed ID: 10703942
    [Abstract] [Full Text] [Related]

  • 13. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W, Wang H, Zhao W, Zhu J, Ju B, Wang X.
    Chin Med J (Engl); 2001 Jan 29; 114(1):30-4. PubMed ID: 11779431
    [Abstract] [Full Text] [Related]

  • 14. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K, Maerz W, Albanell J, Allopenna J, Martin P, Moore MA, Dmitrovsky E.
    Differentiation; 1997 Aug 29; 61(5):321-31. PubMed ID: 9342843
    [Abstract] [Full Text] [Related]

  • 15. Delayed recovery of normal hematopoiesis in arsenic trioxide treatment of acute promyelocytic leukemia: a comparison to all-trans retinoic acid treatment.
    Shinjo K, Takeshita A, Sahara N, Kobayashi M, Nakamura S, Shigeno K, Naito K, Maekawa M, Ohnishi K, Ohno R.
    Intern Med; 2005 Aug 29; 44(8):818-24. PubMed ID: 16157979
    [Abstract] [Full Text] [Related]

  • 16. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK, Gillan E, Quinn JJ, Altman AJ.
    J Pediatr Hematol Oncol; 1998 Aug 29; 20(6):545-7. PubMed ID: 9856675
    [Abstract] [Full Text] [Related]

  • 17. Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
    Jung YS, Cheong HJ, Kim SJ, Kim KH, Lee N, Park HS, Won JH.
    Leuk Res; 2014 Aug 29; 38(8):977-82. PubMed ID: 24953245
    [Abstract] [Full Text] [Related]

  • 18. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D, Mistry AR, Solomon E, Guidez F.
    Cancer Treat Res; 2010 Aug 29; 145():219-35. PubMed ID: 20306254
    [Abstract] [Full Text] [Related]

  • 19. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
    Chen L, Wang J, Hu X, Xu X.
    Hematology; 2014 Jun 29; 19(4):202-7. PubMed ID: 24074286
    [Abstract] [Full Text] [Related]

  • 20. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
    Rego EM, He LZ, Warrell RP, Wang ZG, Pandolfi PP.
    Proc Natl Acad Sci U S A; 2000 Aug 29; 97(18):10173-8. PubMed ID: 10954752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.